Brief: Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis (Apap)

Savara

18/12/2024 21:28

Dec 18 (Reuters) - Savara Inc  SVRA.O :
    * SAVARA INITIATES ROLLING SUBMISSION OF A BIOLOGICS LICENSE
APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
FOR MOLBREEVI* FOR THE POTENTIAL TREATMENT OF AUTOIMMUNE
PULMONARY ALVEOLAR PROTEINOSIS (APAP)
    * SAVARA INC - EXPECTS TO COMPLETE BLA SUBMISSION BY END OF
1Q
2025
    * SAVARA INC - TO REQUEST PRIORITY REVIEW OF BLA

Source text:  ID:nBw7qmtCLa 
Further company coverage:  SVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))